Candel Therapeutics Q2 FY26 net loss widens to $38.9 million; R&D expense more than doubles to $19.8 million

PUBT · 3d ago
Candel Therapeutics Q2 FY26 net loss widens to $38.9 million; R&D expense more than doubles to $19.8 million
  • Candel Therapeutics posted a Q2 2026 net loss of USD 38.9 million, widening from a loss of USD 4.8 million.
  • R&D expense rose to USD 19.8 million from USD 7 million, driven by higher clinical-trial and manufacturing costs.
  • G&A expense increased to USD 6.9 million from USD 4.2 million on higher commercial-readiness and employee-related costs.
  • Cash and cash equivalents climbed to USD 201.6 million at June 30, 2026, with runway expected into Q1 2028.
  • Targets a prostate-cancer BLA for aglatimagene in Q4 2026, with a potential U.S. launch in 2027 if approved.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.